ImmunoACT licenses CAR-T therapy NexCAR19 to Cipla for South Africa, Algeria and Morocco

The licence covers three named African markets and the licensee’s African operating arm (Cipla Africa / Medpro Pharmaceutica) is the commercialising vehicle.


Coverage: The Meridian legal market record (editorial).

The licence covers three named African markets and the licensee's African operating arm (Cipla Africa / Medpro Pharmaceutica) is the commercialising vehicle.

Record ID TX-AFR-2026-0001
Record type Commercial IP transaction
Transaction type Exclusive licence, In-licensing
IP rights not specified by source, regulatory data
Status Signed
Qualifying date 2026-01-20
Sector Life sciences · Pharmaceuticals – cell and gene therapy
African markets South Africa, Algeria, Morocco
Licensed territory South Africa, Algeria and Morocco.
Disclosed value Not disclosed in the sources reviewed.
Evidence Primary source, single · 1 source(s)
Last verified 2026-10-25

Parties

  • ImmunoACT (India): licensor
  • Cipla (India): licensee
  • Medpro (South Africa): licensee, subsidiary

Key terms

  • Interest: exclusive licence to commercialise plus supply arrangement; Exclusivity: exclusive; Territorial scope: South Africa, Algeria, Morocco; Field of use: Relapsed or refractory B-cell non-Hodgkin's lymphoma and B-cell acute lymphoblastic leukaemia

Sources

  1. ImmunoACT partners with Cipla to launch NexCAR19 (Talicabtagene autoleucel) for Blood Cancers in Africa, ImmunoACT (Immunoadoptive Cell Therapy Pvt Ltd), 2026-01-20

Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.